US4315920A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Adenosine deaminase inhibitors
Assignee: SmithKline Beecham Corp
•
Filing: 1980-01-14
•
Granted: 1982-02-16
•
Expires: 2000-01-14
Abstract
Abstract Pharmaceutical preparations containing compounds of the formula ##STR1## where R is alkyl of 1 to 11 carbons. The preparations are useful in inhibiting adenosine deaminase in mammals thereby providing a method for prolonging the effectiveness of pharamaceutical agents which are biologically degraded by adenosine deaminase and thus converted into other compounds.
Inventors
- 👤 Howard J. Schaeffer
- 👤 Paulo M. S. DeMiranda
- 👤 Gertrude B. Elion
- 👤 George H. Hitchings
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 06:27
CPC Classifications
C; C07; C07D; C07D475/00; C07D475/06; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/46; C07D239/48; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
58 words
The method of preventing rapid degradation of 9-β-D-arabinofuranosyladenine or a pharmaceutically acceptable salt thereof in a mammal undergoing systemic treatment with 9-β-D-arabinofuranosyladenine or a pharmaceutically acceptable salt thereof by inhibiting the conversion of 9-β-D-arabinofuranosyladine or a pharmaceutically acceptable salt thereof comprising administering to said mammal an effective degradation inhibition amount of erythro-9-(2-hydroxy-3-nonyl)adenine or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
58 words
The method of preventing rapid degradation of 9-β-D-arabinofuranosyladenine or a pharmaceutically acceptable salt thereof in a mammal undergoing systemic treatment with 9-β-D-arabinofuranosyladenine or a pharmaceutically acceptable salt thereof by inhibiting the conversion of 9-β-D-arabinofuranosyladine or a pharmaceutically acceptable salt thereof comprising administering to said mammal an effective degradation inhibition amount of erythro-9-(2-hydroxy-3-nonyl)adenine or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
38 words
The method of claim 1 in which the mammal is administered the 9-β-D-arabinofuranosyladenine or a pharmaceutically acceptable salt thereof by oral or parenteral administration and said erythro-9-(2-hydroxy-3-nonyl)adenine or a pharmaceutically acceptable salt thereof is administered orally or parenterally.
Claim 4
Dependent Claim
27 words
The method of claim 2 in which said erythro-9-(2-hydroxy-3-nonyl)adenine or a pharmaceutically acceptable salt is administered in a tablet, in a capsule or in an injectable solution.
Claim 5
Dependent Claim
14 words
The method of claim 2 in which 9-β-D-arabinofuranosyladenine is being administered to the mammal.
Claim 6
Dependent Claim
14 words
The method of claim 2 in which the hydrochloride salt of erythro-9-(2-hydroxy-3-nonyl)adenine is administered.
Claim 7
Dependent Claim
14 words
The method of claim 4 in which the hydrochloride salt of erythro-9-(2-hydroxy-3-nonyl)adenine is administered.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-02-15 | 1985-08-17 | 1986-02-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-02-15 | 1989-08-17 | 1990-02-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-02-15 | 1993-08-17 | 1994-02-16 | $7700.00 | Window Closed / Lapsed |